Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on October 29, 2015. The filing reports the company's earnings results for the fiscal quarter and full year ended September 30, 2015, and provides forward-looking guidance for fiscal year 2016.
Key Financial Metrics
The filing text does not provide specific GAAP or non-GAAP values for revenue, profit, cash flow, margins, debt, or liquidity for the reported period. It references a news release (Exhibit 99.1) containing these figures and reconciliations. The text notes that non-GAAP measures adjust for warrant expense, antitrust litigation gains, LIFO expense, acquisition-related intangibles amortization, severance, and a non-recurring impairment charge on an equity investment.
Material Changes
The filing does not explicitly state the percentage or dollar amount of changes in financial metrics compared to the prior period. It indicates that the company utilized non-GAAP measures to evaluate operating performance, adjusting for specific one-time and recurring items to facilitate investor analysis.
Guidance, Outlook, and Management Commentary
Management provided the following expectations for fiscal year 2016 adjusted diluted earnings per share and key assumptions:
- Adjusted Diluted EPS: $5.73 to $5.90.
- Revenue Growth: 8% to 10%.
- Adjusted Operating Income Growth: 16% to 18%.
- Adjusted Operating Margin: Increase of 8 to 12 basis points.
- Effective Tax Rate: Approximately 35.5%.
- Free Cash Flow: $2.3 billion to $2.7 billion.
- Capital Expenditures: Approximately $400 million.
- Acquisition: Assumes completion of the PharMEDium Healthcare Holdings, Inc. acquisition in the first fiscal quarter.
Investor Verification Checklist
- Verify the specific GAAP and non-GAAP revenue, net income, and cash flow figures in the attached news release (Exhibit 99.1).
- Confirm the reconciliation details between GAAP and non-GAAP measures, specifically regarding the non-recurring impairment charge and litigation settlements.
- Monitor the progress and closing date of the PharMEDium Healthcare Holdings acquisition to validate the 2016 guidance assumptions.
- Review the impact of the $600 million senior notes issued for the special share repurchase program on future interest expenses and liquidity.